Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ALS Testing Through Home-based Outcome Measures (ALS AT HOME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03016897
Recruitment Status : Completed
First Posted : January 11, 2017
Last Update Posted : February 8, 2023
Sponsor:
Collaborator:
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Jeremy Shefner, Barrow Neurological Institute

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
ALS AT HOME is a single-center study of up to 150 participants being done to determine the extent to which frequent sampling can improve the qualities of outcome measures collected at home by study participants.

Condition or disease Intervention/treatment
Amyotrophic Lateral Sclerosis Other: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter

Detailed Description:

ALS AT HOME is a single-center study of up to 150 participants being done to determine the extent to which frequent sampling can improve the qualities of outcome measures collected at home by study participants.

The objectives of this study are to

  1. assess the extent to which frequent sampling can reduce variability for the following outcome measures in ALS patients: ALSFRS-R, quantitative hand grip, pulmonary function, EIM in 4 extremities, and actigraphy and voice/speech tracking;
  2. assess the compliance of ALS patients in obtained outcome measures at home over the course of 9 months;
  3. directly compare outcome measures collected by patients with measurements obtained at study sites at less frequent intervals by co-enrolling 50 patients participating in the Answer ALS study; and
  4. provide information to Answer ALS to more fully characterize patients in that study.

The study proposed here will assess the extent to which reducing variability of measurement through frequent sampling can reduce both sample size and duration of clinical trials, provide a first-of-its-kind detailed assessment of disease progression, and evaluate an entirely new paradigm for patient participation in such trials without the need to be geographically yoked to a clinical study center. An important component of this proposal is to jointly recruit 50 patients who also participate in the Answer ALS study that intends to generate 1000 IP cell lines from patients who receive ongoing assessment at 5 clinical sites. The 100 participants that will be co-enrolled in Answer ALS and ALS AT HOME will perform outcome measures at home in addition to having outcome measures performed at clinic sites through Answer ALS participation. Therefore, the investigators will be able to directly assess how the measures obtained by patients at home relate to those obtained by a trained evaluator at a study center using standard metrics. The investigators will also provide all data generated at home to the Answer ALS investigators, further increasing the phenotypic data available for that project.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 144 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: ALS Testing Through Home-based Outcome Measures (ALS AT HOME)
Actual Study Start Date : February 22, 2017
Actual Primary Completion Date : June 28, 2019
Actual Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Group 1
Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
 Other: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Group 2
Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
 Other: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Group 3
Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
 Other: Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Pulmonary Function [ Time Frame: Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly ]
    Respirometer

  2. Change in Quantitative Hand Grip [ Time Frame: Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly ]
    Digital Handgrip Meter

  3. Change in Electrical Impedance Myography (EIM) Measurements [ Time Frame: Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly ]
    Skulpt Chisel

  4. Change in Actigraphy [ Time Frame: Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly ]
    Activity Band

  5. ALSFRS-R [ Time Frame: Weekly up to 9 months ]
    Questionnaire

  6. Change in Patient-reported Experience measures (PREMs) [ Time Frame: At Week 1, and then at 3, 6, and 9 months ]
    Questionnaire

  7. Adverse Events [ Time Frame: Monthly up to 9 months ]
    Questionnaire

  8. Change in Voice/Speech Tracking [ Time Frame: Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly ]
    Smartphone application


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
ALS patient volunteers will be invited to participate in this study as well as healthy subjects for the control group.
Criteria

Inclusion Criteria:

  • male or female, age 18 to 85 years old,
  • ownership of a Smart Device (phone, tablet, etc) with Bluetooth capabilities,
  • continuous internet access at home,
  • willing and able to provide informed consent in compliance with the regulatory requirements through a web based interface,
  • definite, Probable, or Possible ALS by modified El Escorial criteria, as documented by medical records, with duration from diagnosis 60 months or less, and
  • for the 50 participants in Group 2, participation in the Answer ALS study.

Exclusion Criteria:

  • diagnosed and actively undergoing treatment for cancer, heart failure, end stage renal disease, or another significant medical condition deemed by the PI to likely affect the participant's ability to comply with the protocol,
  • unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant's ability to comply with the protocol,
  • any other reasons that, in the opinion of the PI, the candidate is determined to be unsuitable for entry into the study.
  • Healthy volunteers who have family members with ALS
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03016897


Locations
Layout table for location information
United States, Arizona
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
Sponsors and Collaborators
Jeremy Shefner
Beth Israel Deaconess Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Jeremy Shefner, MD Barrow Neurological Institute
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jeremy Shefner, Senior Vice President, Barrow Neurological Institute
ClinicalTrials.gov Identifier: NCT03016897    
Other Study ID Numbers: BNI_ALS_001
First Posted: January 11, 2017    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD may be shared with researchers conducting the Answer ALS study. It will be available through the GUID.
Keywords provided by Jeremy Shefner, Barrow Neurological Institute:
ALS
neurodegenerative
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
 Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases